Themis Medicare Ltd
NSE:THEMISMED
Themis Medicare Ltd
Themis Medicare Ltd. is a holding company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-04-02. The firm is focused on the formulation and active pharmaceutical ingredients (API) activity. Its product category includes star products, differential products, and APIs. Its star products include OD-LM (Levocetrizine 5 mg + Montelukast 10 mg), Medzol (Midazolam hydrochloride 1 ml, 5ml and 10 ml), Cisatra (Cisatracurium 2 mg/ml), and Aquadol (Diclofenac sodium 75mg/ml). Its differential products include Enterofizz-EL (Bacillus clausii + Electrolytes) and Etojet (Etoricoxib 90mg/ml). Its APIs products include Simvastatin, Ketamine Hcl, and Isosorbide Di Methyl Ether (THEMISOL).The Company’s manufacturing locations in India are situated at Vapi, Haridwar and Hyderabad. The firm markets in over 44 countries. Its subsidiaries include Artemis Biotech Limited, Themis Lifestyle Private Limited, and Carpo Medical Limited (UK).
Themis Medicare Ltd. is a holding company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-04-02. The firm is focused on the formulation and active pharmaceutical ingredients (API) activity. Its product category includes star products, differential products, and APIs. Its star products include OD-LM (Levocetrizine 5 mg + Montelukast 10 mg), Medzol (Midazolam hydrochloride 1 ml, 5ml and 10 ml), Cisatra (Cisatracurium 2 mg/ml), and Aquadol (Diclofenac sodium 75mg/ml). Its differential products include Enterofizz-EL (Bacillus clausii + Electrolytes) and Etojet (Etoricoxib 90mg/ml). Its APIs products include Simvastatin, Ketamine Hcl, and Isosorbide Di Methyl Ether (THEMISOL).The Company’s manufacturing locations in India are situated at Vapi, Haridwar and Hyderabad. The firm markets in over 44 countries. Its subsidiaries include Artemis Biotech Limited, Themis Lifestyle Private Limited, and Carpo Medical Limited (UK).
Revenue Growth: Themis Medicare reported Q2 FY24 revenue of INR 104.78 crores, up 15% year-on-year, driven by strong growth in the hospital and domestic trade businesses.
Hospital Segment: Hospital business grew 20% YoY in Q2, with management expecting even higher growth in coming quarters, especially with new product launches like Remithem.
Margin Pressure: EBITDA margin for Q2 dropped to 11.84%, mainly due to higher raw material costs in API and increased manpower expenses to build out hospital teams.
API Strategy: API business is being carved out into a wholly-owned subsidiary (Themis Chemicals) to streamline growth; transition expected to complete by December with minimal financial impact.
Outlook: Management expects significant top-line growth in H2 and future periods, with margin recovery to follow as API customers shift to new manufacturing processes and hospital productivity rises.
CapEx: No major capacity expansion planned; focus remains on contract manufacturing and boosting productivity rather than headcount or fixed costs.
